Tecentriq SC (Atezolizumab)

atezolizumab 1.875 g/15 mL injection, 15 mL vial · INJECTION · PBS code 14289C

STREAMLINED

What it costs

AU$6747.37 PBS-determined price per 1 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2024-08-01.
• Repeats: 3.
• PBS program: CT.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Extensive-stage small cell lung cancer

Initial treatment

The condition must be previously untreated; AND

Patient must not have previously received programmed cell death-1/ligand-1 (PD-1/PD-L1) inhibitor therapy for any stage of small cell lung cancer; AND

Patient must have a WHO performance status of 0 or 1; AND

The treatment must be in combination with etoposide and a platinum-based antineoplastic drug.

Sponsor: Roche Products Pty Ltd ABN 70 000 132 865

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.